These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 2254228)

  • 21. Chloramphenicol resistance in Escherichia coli.
    Smith HW
    J Med Microbiol; 1973 Aug; 6(3):347-50. PubMed ID: 4580063
    [No Abstract]   [Full Text] [Related]  

  • 22. Occurrence of fluoroquinolones and fluoroquinolone-resistance genes in the aquatic environment.
    Adachi F; Yamamoto A; Takakura K; Kawahara R
    Sci Total Environ; 2013 Feb; 444():508-14. PubMed ID: 23291652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of plasmid-mediated quinolone resistance determinants among Escherichia coli isolated from food animals in Korea.
    Tamang MD; Nam HM; Chae MH; Kim SR; Gurung M; Jang GC; Jung SC; Lim SK
    Foodborne Pathog Dis; 2012 Dec; 9(12):1057-63. PubMed ID: 23186547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Distribution of drug-resistance of E. coli and the clinical significance of nalidixic acid].
    Seiga K
    Jpn J Antibiot; 1968 Feb; 21(1):19-24. PubMed ID: 4875185
    [No Abstract]   [Full Text] [Related]  

  • 25. Frequency and expression of mutational resistance to the 4-quinolone antibacterials.
    Smith JT
    Scand J Infect Dis Suppl; 1986; 49():115-23. PubMed ID: 3547618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The comparison of MAMA PCR and SSCP PCR to study chromosomal resistance against Ciprofloxacin and Nalidixic acid in Escherichia coli and Klebsiella pneumoniae.
    Hashemi B; Abdollahi M; Rafiei A; Pormohammad A; Ahanjan M; Moghadaszadeh M; Rashidian S
    Microb Pathog; 2018 Jul; 120():181-186. PubMed ID: 29742463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interactions of the 4-quinolones with other antibacterials.
    Lewin CS; Smith JT
    J Med Microbiol; 1989 Jul; 29(3):221-7. PubMed ID: 2664184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antimicrobial action of nalidixic acid and the effect on the elimination of resident drug-resistant Shigella and E. coli in mice].
    Ogasawara K; Ata S; Kasuya M; Kobayashi T
    Igaku To Seibutsugaku; 1965 Jun; 70(6):343-8. PubMed ID: 5318841
    [No Abstract]   [Full Text] [Related]  

  • 29. Virulence factors in Escherichia coli.
    Johnson JR
    J Clin Microbiol; 2005 Dec; 43(12):6221; author reply 6221-2. PubMed ID: 16333140
    [No Abstract]   [Full Text] [Related]  

  • 30. Fluoroquinolone resistance mechanisms in urinary tract pathogenic Escherichia coli isolated during rapidly increasing fluoroquinolone consumption in a low-use country.
    Christiansen N; Nielsen L; Jakobsen L; Stegger M; Hansen LH; Frimodt-Møller N
    Microb Drug Resist; 2011 Sep; 17(3):395-406. PubMed ID: 21668371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
    Guimaraes MA; Noone P
    J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Character of the effect of nalidixic acid (negram) on Escherichia coli strain 613].
    Planel'es KhKh; Andreeva AM; Moroz AF
    Antibiotiki; 1968 Jul; 13(7):617-20. PubMed ID: 4880236
    [No Abstract]   [Full Text] [Related]  

  • 33. Inhibition of plasmid conjugation by some recently synthetized 4-quinolone compounds.
    Scazzocchio F; Selan L; Oliva B; Schippa S; Cellini L; Renzini G
    Chemioterapia; 1988 Oct; 7(5):295-7. PubMed ID: 3066516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The responses of Escherichia coli to nalidixic acid.
    Greenwood D; O'Grady F
    Chemotherapy; 1978; 24(4):249-58. PubMed ID: 348417
    [No Abstract]   [Full Text] [Related]  

  • 35. Antagonism between bactericidal activities of 4-quinolones and coumarins gives insight into 4-quinolone killing mechanisms.
    Howard BM; Pinney RJ; Smith JT
    Microbios; 1994; 77(311):121-31. PubMed ID: 8152392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo selection during ofloxacin therapy of Escherichia coli with combined topoisomerase mutations that confer high resistance to ofloxacin but susceptibility to nalidixic acid.
    Cattoir V; Lesprit P; Lascols C; Denamur E; Legrand P; Soussy CJ; Cambau E
    J Antimicrob Chemother; 2006 Nov; 58(5):1054-7. PubMed ID: 16984897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo sequential selection of Escherichia coli with topoisomerase- and efflux-mediated misleading quinolone resistance phenotypes.
    Smati M; Emond JP; Arlet G; Tankovic J
    Microb Drug Resist; 2012 Feb; 18(1):19-22. PubMed ID: 22043806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Susceptibility of Campylobacter hyointestinalis subsp. hyointestinalis to antimicrobial agents and characterization of quinolone-resistant strains.
    Laatu M; Rautelin H; Hänninen ML
    J Antimicrob Chemother; 2005 Feb; 55(2):182-7. PubMed ID: 15649999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Quinolone resistance in Salmonella enterica].
    Seral C; López L; Castillo FJ; Clavel A; Rubio MC
    Rev Esp Quimioter; 1998 Mar; 11(1):43-6. PubMed ID: 9795288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Sensitivity of an E. coli strain during therapy of experimental pyelonephritis using nalidixic acid].
    Hatala M; Ritzerfeld W; Prát V; Konícková L; Losse H
    Cas Lek Cesk; 1970 Mar; 109(14):291-6. PubMed ID: 4909024
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.